Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease

2012189 citationsJournal Articlebronze Open Access

Authors

Davangere P. Devanand · New York Psychoanalytic Society and Institute

Jacobo Mintzer

Susan K. Schultz · University of Iowa

Howard Andrews · Nike (United States)

David L. Sultzer · University of California, Los Angeles

Danilo de la Pena · Center for Clinical Studies

Sanjay Gupta · Columbia University

Abstract

In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00417482.).

Topics & Keywords

Schizophrenia research and treatment Dementia and Cognitive Impairment Research Treatment of Major Depression

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 16, pp. 1497-1507

DOI: 10.1056/nejmoa1114058

Field-Weighted Citation Impact: 11.30